Tekcapital plc Technology Acquisition (8030J)
10 Avril 2015 - 8:01AM
UK Regulatory
TIDMTEK
RNS Number : 8030J
Tekcapital plc
10 April 2015
10 April 2015
Tekcapital Plc
("Tekcapital", "the Company" or "the Group")
Technology Acquisition
Tekcapital acquires exclusive licence to a new technology
for the non-invasive measurement of glucose in breath
Tekcapital plc (AIM: TEK), an international provider of
technology and intellectual property services, is pleased to
announce that it has acquired the exclusive license to a
patent-pending technology for the measurement of glucose in breath
from Purdue University. The technologyaddresses the need for a
safe, fast, accurate and non-invasive method for health
professionals to analyse samples of glucose in exhaled breath and
adds to Tekcapital's portfolio of patents for the non-invasive
measurement of glucose which also includes a technology to test for
glucose in saliva.
Glucose is a non-volatile molecule found in exhaled breath
condensates. Accurately measuring the concentration of glucose in
exhaled breath may allow for the non-invasive estimation of glucose
concentration in blood, which in turn could be used for routine
monitoring of the blood glucose concentration in diabetic patients.
Currently, there is no commercially available device to collect
exhaled breath condensate and measure its glucose level.
Purdue University researchers have developed a novel glucose
breath monitor that could reduce the need for invasive glucose
monitoring. The glucose monitor consists of a breath condensing
unit that monitors the temperature, volume, and glucose
concentration of exhaled breath along with a condenser for
background air. The glucose concentration of exhaled breath
condensate is corrected for the humidity and glucose concentration
of background air that could deliver more reliable measurements
compared to those of similar technologies. The blood glucose
concentration is calculated from its correlation with the corrected
glucose concentration in the exhaled breath condensate. The
advantages of this technology is that the sensor system does not
require blood samples while simultaneously reducing measurement
complications that may result from humidity and glucose in air.
Market potential
The World Health Organisation estimates that diabetes is the
eighth largest cause of death globally. There are 29.1 million
Americans living with diabetes, a disease that leads to a 50%
higher risk of death in adults. Monitoring blood glucose is one
crucial aspect of diabetes management. Currently, monitoring blood
glucose requires direct FDA-approved measurement from a blood
sample, using a lance, strips and glucometer. This inconvenient and
invasive monitoring technique often discourages patients from
making the frequent measurements needed for careful regulation of
glucose.
The Directors believe that a non-invasive technology to
accurately measure glucose in breath could be transformative to
both patients and the glucose monitoring industry. If successful, a
glucose breathalyser may become one of the monitoring techniques of
choice for professionals in hospitals, clinics, doctor offices and
schools.
Commenting on the announcement, Dr. Clifford M. Gross, Executive
Chairman of Tekcapital plc, said:
"We are excited to have acquired the exclusive license to this
important technology developed by Purdue University for the
measurement of glucose in breath. This technology strengthens our
portfolio of IP for the non-invasive measurement of glucose and we
look forward to commercialising it with one or more leading medical
device companies that can benefit by making it easier and painless
for professionals to measure glucose in their patients and for
health screening applications."
For further information please contact:
Tekcapital plc +1 305 200 3450
Ext 305
Clifford M. Gross cgross@tekcapital.com
Purdue University +1 765 588 3340
Cynthia Sequin casequin@prf.org
Allenby Capital Ltd (Nominated +44 (0)20 3328
Adviser & Joint Broker) 5656
Jeremy Porter / Alex Brearley
Optiva Securities Limited +44 (0) 20 3137
(Joint Broker) 1904
Jeremy King / Vishal Balasingham jeremy.king@optivasecurities.com
+44 (0) 20 3727
FTI Consulting, LLP 1000
Chris Lane / Emma Appleton
/ Roger Newby tekcapital@fticonsulting.com
Tekcapital plc - The World's Largest University Network for Open
Innovation
Tekcapital helps clients profit from new, university-developed
intellectual properties. With our proprietary discovery search
engine, linked to 4,000+ universities in 160 countries, coupled
with expert scientific review, we provide a turn-key service to
make it easy for clients to find and acquire the IP they need to
create a competitive advantage. Tekcapital plc is listed on the AIM
market of the London Stock Exchange (AIM: symbol TEK) and is
headquartered in Oxford, in the UK. For more information, please
visit www.tekcapital.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
ACQDGGDSCXGBGUC
Tekcapital (LSE:TEK)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Tekcapital (LSE:TEK)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024